Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 2 completion70d agoInstitute of Liver and Biliary Sciences — darbepoetin alfa (Phase II Trial Completion)darbepoetin alfa

Therapy area: Gastrointestinal. Indication: Decompensated Cirrhosis, Liver Cirrhosis

full page →darbepoetin alfa →source: globaldata

Apr 30, 2026phase 2 completion70d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion70d agoAristotle University of Thessaloniki — oleocanthal (Phase II Trial Completion)oleocanthal

Therapy area: Central Nervous System. Indication: Mild Cognitive Impairment

full page →oleocanthal →source: globaldata

Apr 30, 2026phase 2 completion70d agoBiogen Inc — DNL-151 (Phase II Trial Completion)DNL-151

Therapy area: Central Nervous System. Indication: Parkinson's Disease

full page →DNL-151 →source: globaldata

Apr 30, 2026phase 2 completion70d agoAffiliated Stomatological Hospital of Guangxi Medical University — autologous platelet rich plasma (Phase II Trial Completion)autologous platelet rich plasma

Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Arthralgia (Joint Pain), Osteoarthritis

full page →autologous platelet rich plasma →source: globaldata

Apr 30, 2026phase 2 completion70d agoVertex Pharmaceuticals Inc — VX-993 (Phase II Trial Completion)VX-993

Therapy area: Central Nervous System. Indication: Diabetic Peripheral Neuropathy, Peripheral Neuropathic Pain

full page →VX-993 →source: globaldata

Apr 30, 2026phase 2 completion70d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

full page →recombinant type III humanized collagen →source: globaldata

Apr 30, 2026phase 2 completion70d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

Therapy area: Oncology. Indication: Soft Tissue Sarcoma

full page →fuzuloparib →source: globaldata

Apr 30, 2026phase 2 completion70d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

Therapy area: Oncology. Indication: Neuroblastoma

full page →ISOTRETINOIN →source: globaldata

Apr 30, 2026phase 2 completion70d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

full page →ghrelin →source: globaldata

Apr 30, 2026phase 2 completion70d agoFundacion para la Investigacion Biomedica Hospital Clinico San Carlos — cromolyn sodium (Phase II Trial Completion)Gastrocrom

Therapy area: Central Nervous System. Indication: Multiple Sclerosis

full page →Gastrocrom →source: globaldata

Apr 30, 2026phase 2 completion70d agoGachon University Gil Medical Center — Wegovy (Phase II Trial Completion)Wegovy Pill

Therapy area: Metabolic Disorders. Indication: Obesity

full page →Wegovy Pill →source: globaldata

Apr 30, 2026phase 2 completion70d agoWannan Medical College First Affiliated Hospital — dexmedetomidine (Phase II Trial Completion)dexmedetomidine

Therapy area: Undisclosed. Indication: Unspecified

full page →dexmedetomidine →source: globaldata

Apr 30, 2026phase 2 completion70d agoWestern New England University — grape powder (Phase II Trial Completion)grape powder

Therapy area: Central Nervous System. Indication: Cognitive Disorders

full page →grape powder →source: globaldata

Apr 30, 2026phase 2 completion70d agoKLE College of Pharmacy, Belagavi — undisclosed immunosuppressive drug (Phase II Trial Completion)undisclosed immunosuppressive drug

Therapy area: Genito Urinary System. Indication: Nephrotic Syndrome

full page →undisclosed immunosuppressive drug →source: globaldata

Apr 30, 2026phase 2 completion70d agoUniversity of Minnesota — Lactobacillus casei (Phase II Trial Completion)Lactobacillus casei

Therapy area: Musculoskeletal Disorders. Indication: Muscle Injury, Unspecified Musculoskeletal Disorders

full page →Lactobacillus casei →source: globaldata

Apr 30, 2026phase 2 completion70d agoArrae Inc — Aframomum melegueta extract (Phase II Trial Completion)Aframomum melegueta extract

Therapy area: Metabolic Disorders. Indication: Obesity, Overweight

full page →Aframomum melegueta extract →source: globaldata

Apr 30, 2026phase 2 completion70d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata

Apr 30, 2026phase 2 completion70d agoCharak Ayurvedic Pharmacy, Paprola — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Metabolic Disorders, Musculoskeletal Disorders. Indication: Hyperuricemia, Unspecified Musculoskeletal Disorders

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 2 completion70d agoBuddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)dexamethasone

Therapy area: Musculoskeletal Disorders. Indication: Bone Fracture

full page →dexamethasone →source: globaldata

Apr 30, 2026phase 2 completion70d agoHuadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)LIDOCAINE

Therapy area: Respiratory. Indication: Cough

full page →LIDOCAINE →source: globaldata

Apr 30, 2026phase 2 completion70d agoChongqing Medical University Hospital 2 — propofol (Phase II Trial Completion)PROPOFOL

Therapy area: Central Nervous System. Indication: Cognitive Disorders

full page →PROPOFOL →source: globaldata

Apr 30, 2026phase 2 completion70d agoHematology Hospital of Chinese Academy of Medical Sciences — letermovir (Phase II Trial Completion)letermovir

Therapy area: Undisclosed. Indication: Unspecified

full page →letermovir →source: globaldata

Apr 30, 2026phase 2 completion70d agoCantonal Hospital Authority — bupivacaine (Phase II Trial Completion)bupivacaine

Therapy area: Central Nervous System. Indication: Post-Operative Pain

full page →bupivacaine →source: globaldata

Apr 30, 2026phase 2 completion70d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

Apr 30, 2026phase 2 completion70d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

Therapy area: Oncology. Indication: Prostate Cancer

full page →atezolizumab →source: globaldata

Apr 30, 2026phase 2 completion70d agoNoster Inc — 10-hydroxy-cis-12- octadecenoic acid (Phase II Trial Completion)10-hydroxy-cis-12- octadecenoic acid

Therapy area: Metabolic Disorders. Indication: Type 1 Diabetes (Juvenile Diabetes)

full page →10-hydroxy-cis-12- octadecenoic acid →source: globaldata

Apr 30, 2026phase 2 completion70d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion70d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

Therapy area: Oncology. Indication: Colorectal Cancer

full page →capecitabine →source: globaldata

Apr 30, 2026phase 2 completion70d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion70d agoLifeArc — fecal microbiota (Phase II Trial Completion)fecal microbiota

Therapy area: Gastrointestinal. Indication: Inflammatory Bowel Disease, Primary Sclerosing Cholangitis

full page →fecal microbiota →source: globaldata

Apr 30, 2026phase 2 completion70d agoNational Cheng-Kung University Hospital — SynPro-15G (Phase II Trial Completion)SynPro-15G

Therapy area: Gastrointestinal. Indication: Irritable Bowel Syndrome

full page →SynPro-15G →source: globaldata

Apr 30, 2026phase 2 completion70d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 2 completion70d agoEmory University — (carbidopa + levodopa) (Phase II Trial Completion)(carbidopa + levodopa)

Therapy area: Central Nervous System. Indication: Cognitive Disorders, Depression

full page →(carbidopa + levodopa) →source: globaldata

Date TBD

TBDapprovalOZURDEX (DEXAMETHASONE) — FDA approvaldexamethasone LA

Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL

full page →dexamethasone LA →fda approvals ↗

TBDapproval

← prev

page 6 of 6

Week of Apr 27, 2026

Date TBD